Tag: sustained release excipients market forecast

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Sustained Release Excipients Market Size, Value And Growth Trajectory Through 2030

The sustained release excipients market size has experienced significant growth in recent years. It is forecast to increase from $1.51 billion in 2025 to $1.63 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.2%. This historical growth can be attributed to several factors, including the increasing prevalence of chronic diseases, a rise in the use of modified release tablets, developments in polymer chemistry, the expansion of generic drug manufacturing, and the regulatory acceptance of sustained release formulations.

The sustained release excipients market size is anticipated to experience substantial expansion in the coming years. This market is projected to reach $2.3 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.9%. Factors contributing to this expansion over the forecast period include the escalating demand for long-acting injectables, the expansion of biologics and specialty drugs, increased spending on drug delivery research and development, the need for patient-focused formulations, and the widening scope of pharmaceutical production in developing regions. Key trends emerging during this period encompass a growing desire for controlled drug delivery methods, the increased incorporation of polymers into sustained release compositions, the rising acceptance of oral sustained release dosage formats, advancements in microencapsulation and coacervation techniques, and an emphasis on improving patient adherence and minimizing dosage frequency.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=70041045&type=smp&name=Sustained%20Release%20Excipients%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Sustained Release Excipients Market Growth Backed By Core Demand Fundamentals

The increasing demand for individualized medicine is anticipated to drive the expansion of the sustained-release excipients market in the future. Personalized medicine, also known as personalized care, involves healthcare providers examining patients’ distinct genes, proteins, and other physiological elements to deliver and manage tailored treatments through precision medicine. These sustained-release excipients are vital in personalized medicine, facilitating the creation of drug formulations specifically adapted for individual patient requirements. As an example, in February 2024, data from the Personalised Medicine Coalition, a US-based hospital and health care organization, indicated that in 2023, the FDA sanctioned 16 novel personalized treatments for patients with rare diseases, an increase from 6 in 2022. Consequently, the rising demand for personalized medicine is fueling the growth of the sustained-release excipients market.

Sustained Release Excipients Market Segment Performance And Emerging Opportunities

The sustained release excipients market covered in this report is segmented –

1) By Product: Gelatin, Polymers, Minerals, Chitosan

2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration

3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation

Subsegments:

1) By Gelatin: Type A Gelatin, Type B Gelatin

2) By Polymers: Natural Polymers, Synthetic Polymers

3) By Minerals: Calcium Compounds, Magnesium Compounds, Other Mineral Excipients

4) By Chitosan: Low Molecular Weight Chitosan, High Molecular Weight Chitosan

Sustained Release Excipients Market Growth Trends Reshaping The Competitive Landscape

Leading companies in the sustained release excipients market are concentrating on developing sophisticated solutions, such as multifunctional polymer platforms, to improve drug formulation efficiency, reduce delivery durations, and enable precise controlled-release profiles. These multifunctional polymer platforms are excipients designed to facilitate immediate, delayed, and sustained drug release, and they are compatible with formulation techniques such as hot melt extrusion and solubility-enhancing spray drying. As an example, in September 2024, Evonik, a Germany-based company, initiated the operation of a new spray drying facility located at its Darmstadt site, specifically for EUDRAGIT polymers. This new facility boosts production capacity, shortens delivery periods, and is completely integrated into existing production systems. It utilizes green electricity and steam generated from local waste incineration, leading to an annual reduction of CO2 emissions by over 1,000 tons. The facility operates under IPEC-GMP pharmaceutical guidelines and is directly linked to the production of aqueous dispersions, thereby minimizing transportation needs and optimizing the supply chain. The polymers manufactured at this site facilitate immediate, delayed, and sustained release formulations, thereby solidifying Evonik’s position as a global center for oral drug delivery solutions and enhancing its capacity to efficiently back innovative pharmaceutical advancements.

Sustained Release Excipients Market Key Players: Which Companies Lead Industry Competition?

Major companies operating in the sustained release excipients market are BASF SE, Ashland Global Holdings Inc, Colorcon Inc, Evonik Industries AG, Lubrizol Corporation, Merck KGaA, Roquette Freres, Shin Etsu Chemical Co Ltd, JRS Pharma GmbH Co KG, SPI Pharma Inc, Croda International Plc, Lonza Group AG, Chemische Fabrik Budenheim KG, Asahi Kasei Corporation, DuPont de Nemours Inc, Dow Chemical Company, Eastman Chemical Company, Gattefosse SAS, Balchem Corporation, Associated British Foods plc, Ransom Naturals Ltd, Cellulose Solutions Private Limited

View The Full Sustained Release Excipients Market Report:

https://thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Sustained Release Excipients Market Geographic Spread And Regional Opportunities

North America was the largest region in the global sustained release excipients market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Sustained Release Excipients Market Expansion Outlook: What Revenue Opportunities Lie Ahead?

The market for sustained release excipients has seen robust expansion over the past few years. Its value is projected to climb from $1.51 billion in 2025 to $1.63 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.2%. During the historic period, this growth has been driven by several factors, including rising rates of chronic diseases, a greater adoption of modified release tablets, progress in polymer chemistry, increased production of generic drugs, and wider regulatory acceptance of sustained release formulations.

The sustained release excipients market is projected to experience significant expansion over the coming years. By 2030, its value is anticipated to reach $2.3 billion, reflecting a compound annual growth rate (CAGR) of 8.9%. This upward trajectory during the forecast period is driven by several factors, including a heightened need for long-acting injectables, the expansion of biologics and specialty pharmaceuticals, increased funding for drug delivery research and development, a shift toward patient-focused formulations, and the growth of pharmaceutical production in emerging economies. Key developments shaping the market include a growing preference for controlled drug release systems, wider application of polymers in sustained release products, greater uptake of oral sustained release dosage forms, advancements in microencapsulation and coacervation techniques, and an emphasis on improving patient adherence while lowering dosing frequency.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10822&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Sustained Release Excipients Market Demand Drivers: What Is Fueling Industry Growth?

The increasing need for tailored therapeutic approaches is anticipated to boost expansion within the sustained-release excipients market in the coming period. This method, known as personalized medicine or individualized care, involves healthcare providers examining a patient’s distinct genetic makeup, proteins, and other biological characteristics to design and implement specifically customized treatment through precision-based techniques. Sustained-release excipients are integral to this field, as they facilitate the creation of drug delivery systems that are specifically adapted to the unique requirements of each person. For example, data from the Personalised Medicine Coalition, a healthcare organization located in the United States, indicates that in February 2024, the number of newly approved personalized treatments for rare diseases by the FDA reached 16 in 2023, a significant increase from the 6 recorded in 2022. Consequently, the rising demand for individualized medicine is fueling the onward development of the sustained-release excipients market.

Sustained Release Excipients Market Segment Analysis Highlighting Growth Areas

The sustained release excipients market covered in this report is segmented –

1) By Product: Gelatin, Polymers, Minerals, Chitosan

2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration

3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation

Subsegments:

1) By Gelatin: Type A Gelatin, Type B Gelatin

2) By Polymers: Natural Polymers, Synthetic Polymers

3) By Minerals: Calcium Compounds, Magnesium Compounds, Other Mineral Excipients

4) By Chitosan: Low Molecular Weight Chitosan, High Molecular Weight Chitosan

Sustained Release Excipients Market Innovation Trends: Which Developments Are Transforming The Industry?

Leading players in the sustained release excipients sector are prioritizing the creation of sophisticated solutions, particularly multifunctional polymer platforms, aimed at improving drug formulation efficiency, shortening delivery timelines, and enabling controlled-release mechanisms. These platforms serve as excipients capable of facilitating immediate, delayed, and sustained drug release while maintaining compatibility with formulation techniques such as hot melt extrusion and solubility-enhancing spray drying. A case in point is September 2024, when Evonik—a Germany-based company—commenced operations at a new spray drying facility located at its Darmstadt site, dedicated to EUDRAGIT polymers. This facility boosts production capacity, cuts delivery durations, and is seamlessly incorporated into existing production networks. It relies on green electricity and steam sourced from local waste incineration, achieving an annual reduction in CO2 emissions exceeding 1,000 tons. Adhering to IPEC-GMP pharmaceutical guidelines and directly linked to the production of aqueous dispersions, the facility lessens transportation needs and optimizes supply chain flow. The polymers produced here enable immediate, delayed, and sustained release formulations, thereby bolstering Evonik’s status as a global center for oral drug delivery solutions and reinforcing its capacity to efficiently support innovative pharmaceutical development.

Sustained Release Excipients Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the sustained release excipients market are BASF SE, Ashland Global Holdings Inc, Colorcon Inc, Evonik Industries AG, Lubrizol Corporation, Merck KGaA, Roquette Freres, Shin Etsu Chemical Co Ltd, JRS Pharma GmbH Co KG, SPI Pharma Inc, Croda International Plc, Lonza Group AG, Chemische Fabrik Budenheim KG, Asahi Kasei Corporation, DuPont de Nemours Inc, Dow Chemical Company, Eastman Chemical Company, Gattefosse SAS, Balchem Corporation, Associated British Foods plc, Ransom Naturals Ltd, Cellulose Solutions Private Limited

Access The Complete Sustained Release Excipients Market Report:

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Sustained Release Excipients Market Geographic Analysis: Where Is Demand Growing The Fastest?

North America was the largest region in the global sustained release excipients market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Sustained Release Excipients Market Expansion Outlook: What Revenue Opportunities Lie Ahead?

The market for sustained release excipients has seen robust expansion over the past few years. Its value is projected to climb from $1.51 billion in 2025 to $1.63 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.2%. During the historic period, this growth has been driven by several factors, including rising rates of chronic diseases, a greater adoption of modified release tablets, progress in polymer chemistry, increased production of generic drugs, and wider regulatory acceptance of sustained release formulations.

The sustained release excipients market is projected to experience significant expansion over the coming years. By 2030, its value is anticipated to reach $2.3 billion, reflecting a compound annual growth rate (CAGR) of 8.9%. This upward trajectory during the forecast period is driven by several factors, including a heightened need for long-acting injectables, the expansion of biologics and specialty pharmaceuticals, increased funding for drug delivery research and development, a shift toward patient-focused formulations, and the growth of pharmaceutical production in emerging economies. Key developments shaping the market include a growing preference for controlled drug release systems, wider application of polymers in sustained release products, greater uptake of oral sustained release dosage forms, advancements in microencapsulation and coacervation techniques, and an emphasis on improving patient adherence while lowering dosing frequency.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10822&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Sustained Release Excipients Market Demand Drivers: What Is Fueling Industry Growth?

The increasing need for tailored therapeutic approaches is anticipated to boost expansion within the sustained-release excipients market in the coming period. This method, known as personalized medicine or individualized care, involves healthcare providers examining a patient’s distinct genetic makeup, proteins, and other biological characteristics to design and implement specifically customized treatment through precision-based techniques. Sustained-release excipients are integral to this field, as they facilitate the creation of drug delivery systems that are specifically adapted to the unique requirements of each person. For example, data from the Personalised Medicine Coalition, a healthcare organization located in the United States, indicates that in February 2024, the number of newly approved personalized treatments for rare diseases by the FDA reached 16 in 2023, a significant increase from the 6 recorded in 2022. Consequently, the rising demand for individualized medicine is fueling the onward development of the sustained-release excipients market.

Sustained Release Excipients Market Segment Analysis Highlighting Growth Areas

The sustained release excipients market covered in this report is segmented –

1) By Product: Gelatin, Polymers, Minerals, Chitosan

2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration

3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation

Subsegments:

1) By Gelatin: Type A Gelatin, Type B Gelatin

2) By Polymers: Natural Polymers, Synthetic Polymers

3) By Minerals: Calcium Compounds, Magnesium Compounds, Other Mineral Excipients

4) By Chitosan: Low Molecular Weight Chitosan, High Molecular Weight Chitosan

Sustained Release Excipients Market Innovation Trends: Which Developments Are Transforming The Industry?

Leading players in the sustained release excipients sector are prioritizing the creation of sophisticated solutions, particularly multifunctional polymer platforms, aimed at improving drug formulation efficiency, shortening delivery timelines, and enabling controlled-release mechanisms. These platforms serve as excipients capable of facilitating immediate, delayed, and sustained drug release while maintaining compatibility with formulation techniques such as hot melt extrusion and solubility-enhancing spray drying. A case in point is September 2024, when Evonik—a Germany-based company—commenced operations at a new spray drying facility located at its Darmstadt site, dedicated to EUDRAGIT polymers. This facility boosts production capacity, cuts delivery durations, and is seamlessly incorporated into existing production networks. It relies on green electricity and steam sourced from local waste incineration, achieving an annual reduction in CO2 emissions exceeding 1,000 tons. Adhering to IPEC-GMP pharmaceutical guidelines and directly linked to the production of aqueous dispersions, the facility lessens transportation needs and optimizes supply chain flow. The polymers produced here enable immediate, delayed, and sustained release formulations, thereby bolstering Evonik’s status as a global center for oral drug delivery solutions and reinforcing its capacity to efficiently support innovative pharmaceutical development.

Sustained Release Excipients Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the sustained release excipients market are BASF SE, Ashland Global Holdings Inc, Colorcon Inc, Evonik Industries AG, Lubrizol Corporation, Merck KGaA, Roquette Freres, Shin Etsu Chemical Co Ltd, JRS Pharma GmbH Co KG, SPI Pharma Inc, Croda International Plc, Lonza Group AG, Chemische Fabrik Budenheim KG, Asahi Kasei Corporation, DuPont de Nemours Inc, Dow Chemical Company, Eastman Chemical Company, Gattefosse SAS, Balchem Corporation, Associated British Foods plc, Ransom Naturals Ltd, Cellulose Solutions Private Limited

Access The Complete Sustained Release Excipients Market Report:

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Sustained Release Excipients Market Geographic Analysis: Where Is Demand Growing The Fastest?

North America was the largest region in the global sustained release excipients market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Does The Forecasted Market Size Of The Sustained Release Excipients Market Compare Between 2026 And 2030?

The sustained release excipients market has demonstrated strong expansion over recent years. It is projected to increase from $1.51 billion in 2025 to $1.63 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.2%. This historical growth can be ascribed to several contributing factors, including the rising prevalence of chronic diseases, the greater utilization of modified release tablets, advancements in polymer chemistry, the expansion of generic drug manufacturing, and the regulatory acceptance of sustained release formulations.

The sustained release excipients market size is anticipated to experience substantial growth over the next few years. Its valuation is projected to reach $2.3 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.9%. This expansion during the forecast period is primarily driven by an increasing demand for long-acting injectables, the rise of biologics and specialty drugs, greater investment in drug delivery research and development, the need for patient-centric formulations, and the expansion of pharmaceutical manufacturing operations in developing markets. Significant trends expected in the forecast period involve a growing preference for controlled drug delivery systems, the increased utilization of polymers in sustained release formulations, wider adoption of oral sustained release dosage forms, the advancement of microencapsulation and coacervation technologies, and a focus on enhancing patient compliance through reduced dosing frequency.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10822&type=smp

What Important Drivers Are Powering The Sustained Release Excipients Market Growth?

The sustained-release excipients market is projected to grow as the demand for personalized medicine continues to rise. Personalized medicine, also termed personalized care, involves medical professionals examining patients’ unique genes, proteins, and other biological components to deliver and organize tailored care using precision medicine. Sustained-release excipients are crucial in personalized medicine because they enable the development of drug formulations customized to meet individual patient needs. For instance, in February 2024, the Personalised Medicine Coalition, a US-based hospital and health care organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, which is an increase from 6 in 2022. Thus, the escalating demand for personalized medicine is propelling the expansion of the sustained-release excipients market.

Which Segment Divisions Form The Structure Of The Sustained Release Excipients Market?

The sustained release excipients market covered in this report is segmented –

1) By Product: Gelatin, Polymers, Minerals, Chitosan

2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration

3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation

Subsegments:

1) By Gelatin: Type A Gelatin, Type B Gelatin

2) By Polymers: Natural Polymers, Synthetic Polymers

3) By Minerals: Calcium Compounds, Magnesium Compounds, Other Mineral Excipients

4) By Chitosan: Low Molecular Weight Chitosan, High Molecular Weight Chitosan

What Trends Are Shaping The Sustained Release Excipients Market Structure?

Leading companies within the sustained release excipients market are prioritizing the development of advanced solutions, such as multifunctional polymer platforms, to enhance drug formulation efficiency, decrease delivery duration, and support controlled-release profiles. Multifunctional polymer platforms denote excipients capable of enabling immediate, delayed, and sustained drug release, while remaining compatible with formulation technologies like hot melt extrusion and solubility-enhancing spray drying. For example, in September 2024, Evonik, a company based in Germany, began operating a new spray drying facility at its Darmstadt location specifically for EUDRAGIT polymers. This facility boosts production capacity, shortens delivery times, and integrates completely with existing production networks. It employs green electricity and steam derived from local waste incineration to cut CO2 emissions by over 1,000 tons each year. Adhering to IPEC-GMP pharmaceutical guidelines and being directly connected to the production of aqueous dispersions, the facility reduces transportation and streamlines the supply chain. The polymers manufactured there support immediate, delayed, and sustained release formulations, thereby solidifying Evonik’s global hub for oral drug delivery solutions and strengthening its capability to efficiently support innovative pharmaceutical development.

Which Firms Are Competing In The Sustained Release Excipients Market?

Major companies operating in the sustained release excipients market are BASF SE, Ashland Global Holdings Inc, Colorcon Inc, Evonik Industries AG, Lubrizol Corporation, Merck KGaA, Roquette Freres, Shin Etsu Chemical Co Ltd, JRS Pharma GmbH Co KG, SPI Pharma Inc, Croda International Plc, Lonza Group AG, Chemische Fabrik Budenheim KG, Asahi Kasei Corporation, DuPont de Nemours Inc, Dow Chemical Company, Eastman Chemical Company, Gattefosse SAS, Balchem Corporation, Associated British Foods plc, Ransom Naturals Ltd, Cellulose Solutions Private Limited

Access The Complete Sustained Release Excipients Market Report:

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report

Which Region Is The Primary Market For The Sustained Release Excipients Market?

North America was the largest region in the global sustained release excipients market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Sustained Release Excipients Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=10822&type=smp

Browse Through More Reports Similar to the Global Sustained Release Excipients Market 2026, By The Business Research Company

Sustained Release Excipients Market Report 2026

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report

Pharmaceutical Excipient Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-excipient-global-market-report

Controlled Release Drug Delivery Market Report 2026

https://www.thebusinessresearchcompany.com/report/controlled-release-drug-delivery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Sustained Release Excipients Market Over The Period 2026–2030?

The sustained release excipients market has experienced substantial growth in recent years. It is anticipated to increase from $1.51 billion in 2025 to $1.63 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.2%. The historical expansion of this market can be attributed to several factors, including an increase in chronic disease prevalence, the growing adoption of modified release tablets, innovations in polymer chemistry, the expansion of generic drug manufacturing, and the regulatory acceptance of sustained release formulations.

The sustained release excipients market is anticipated to experience robust expansion in the coming years. It is projected to reach $2.3 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.9%. This growth during the projected period is attributable to several factors, including an increased demand for long-acting injectables, the expansion of biologics and specialty drugs, greater investment in drug delivery research and development, a call for patient-centric formulations, and the widening of pharmaceutical manufacturing operations in developing economies. Key trends anticipated within the forecast timeframe encompass an escalating demand for controlled drug delivery systems, the expanded application of polymers in sustained release formulations, a surge in the adoption of oral sustained release dosage forms, the advancement of microencapsulation and coacervation technologies, and an emphasis on enhancing patient compliance coupled with a reduction in dosing frequency.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10822&type=smp

Which Major Factors Are Driving The Expansion Of The Sustained Release Excipients Market?

The sustained-release excipients market is anticipated to expand due to the increasing need for personalized medicine. Personalized medicine, also known as personalized care, involves medical practitioners examining patients’ distinct genes, proteins, and other physiological elements to deliver and manage customized treatment through precision medicine. These excipients are vital in personalized medicine, facilitating the creation of drug formulations specifically adapted to each patient’s requirements. An example of this trend is seen in February 2024, when the Personalised Medicine Coalition, a US-based hospital and health care organization, reported that the FDA cleared 16 new personalized treatments for rare disease patients in 2023, an increase from 6 in 2022. Consequently, the rising demand for personalized medicine is fueling expansion in the sustained-release excipients market.

How Is The Sustained Release Excipients Market Divided Into Its Major Segments?

The sustained release excipients market covered in this report is segmented –

1) By Product: Gelatin, Polymers, Minerals, Chitosan

2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration

3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation

Subsegments:

1) By Gelatin: Type A Gelatin, Type B Gelatin

2) By Polymers: Natural Polymers, Synthetic Polymers

3) By Minerals: Calcium Compounds, Magnesium Compounds, Other Mineral Excipients

4) By Chitosan: Low Molecular Weight Chitosan, High Molecular Weight Chitosan

How Are Trends Transforming The Sustained Release Excipients Market Landscape?

Leading companies in the sustained release excipients market are concentrating on developing advanced solutions, such as multifunctional polymer platforms, to enhance drug formulation efficiency, reduce delivery time, and support controlled-release profiles. These multifunctional polymer platforms refer to excipients that enable immediate, delayed, and sustained drug release while being compatible with formulation technologies like hot melt extrusion and solubility-enhancing spray drying. For instance, in September 2024, Evonik, a Germany-based company, commenced operations of a new spray drying facility at its Darmstadt site for EUDRAGIT polymers. This facility boosts production capacity, shortens delivery times, and integrates seamlessly with existing production networks. It leverages green electricity and steam from local waste incineration to decrease CO2 emissions by over 1,000 tons annually. Operating under IPEC-GMP pharmaceutical guidelines and directly connected to the production of aqueous dispersions, the facility minimizes transportation and streamlines the supply chain. The polymers manufactured there support immediate, delayed, and sustained release formulations, thereby strengthening Evonik’s global hub for oral drug delivery solutions and reinforcing its capability to efficiently support innovative pharmaceutical development.

Who Are The Prominent Organizations Shaping The Sustained Release Excipients Market?

Major companies operating in the sustained release excipients market are BASF SE, Ashland Global Holdings Inc, Colorcon Inc, Evonik Industries AG, Lubrizol Corporation, Merck KGaA, Roquette Freres, Shin Etsu Chemical Co Ltd, JRS Pharma GmbH Co KG, SPI Pharma Inc, Croda International Plc, Lonza Group AG, Chemische Fabrik Budenheim KG, Asahi Kasei Corporation, DuPont de Nemours Inc, Dow Chemical Company, Eastman Chemical Company, Gattefosse SAS, Balchem Corporation, Associated British Foods plc, Ransom Naturals Ltd, Cellulose Solutions Private Limited

Read the full sustained release excipients market report here:

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report

Which Region Currently Holds The Largest Share Of The Sustained Release Excipients Market?

North America was the largest region in the global sustained release excipients market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Sustained Release Excipients Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10822&type=smp

Browse Through More Reports Similar to the Global Sustained Release Excipients Market 2026, By The Business Research Company

Sustained Release Excipients Market Report 2026

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report

Pharmaceutical Excipient Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-excipient-global-market-report

Controlled Release Drug Delivery Market Report 2026

https://www.thebusinessresearchcompany.com/report/controlled-release-drug-delivery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the sustained release excipients market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Sustained Release Excipients Market in 2026, and what figure is it projected to hit by 2030?

The sustained release excipients market size has experienced robust expansion in recent years. This market is projected to expand from $1.51 billion in 2025 to $1.63 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.2%. Historically, this increase can be linked to factors such as the rising incidence of chronic diseases, a greater adoption of modified release tablets, progress in polymer chemistry, the proliferation of generic drug manufacturing, and the regulatory endorsement of sustained release formulations.

The sustained release excipients market is projected to experience robust expansion over the coming years, reaching $2.3 billion by 2030, with a compound annual growth rate (CAGR) of 8.9%. This anticipated growth during the forecast period is driven by several factors, including the increasing demand for long-acting injectables, the expansion of biologics and specialty drugs, growing investments in drug delivery research and development, the need for patient-centric formulations, and the increased presence of pharmaceutical manufacturing in emerging markets. Significant trends expected during this period encompass a rising demand for controlled drug delivery systems, the expanding utilization of polymers in sustained release formulations, a greater adoption of oral sustained release dosage forms, the development of microencapsulation and coacervation technologies, and a focus on improving patient compliance by reducing dosing frequency.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10822&type=smp

Which Drivers Are Affecting Market Participation In The Sustained Release Excipients Market?

The increasing need for personalized medicine is projected to boost the expansion of the sustained-release excipients market. Personalized medicine, also known as personalized care, involves medical experts analyzing a patient’s distinct genetic makeup, proteins, and other biological elements to deliver and manage tailored care through precision medicine. Within personalized medicine, sustained-release excipients are vital as they facilitate the creation of drug formulations specifically designed for the requirements of individual patients. As an illustration, in February 2024, data from the Personalised Medicine Coalition, a US-based hospital and health care organization, showed that in 2023, the FDA granted approval to 16 new personalized treatments for rare disease patients, marking an increase from 6 approvals in 2022. Consequently, the rising demand for personalized medicine is propelling the sustained-release excipients market forward.

What Segment Categories Are Covered In The Sustained Release Excipients Market?

The sustained release excipients market covered in this report is segmented –

1) By Product: Gelatin, Polymers, Minerals, Chitosan

2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration

3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation

Subsegments:

1) By Gelatin: Type A Gelatin, Type B Gelatin

2) By Polymers: Natural Polymers, Synthetic Polymers

3) By Minerals: Calcium Compounds, Magnesium Compounds, Other Mineral Excipients

4) By Chitosan: Low Molecular Weight Chitosan, High Molecular Weight Chitosan

Which Competitive Trends Are Impacting The Structure Of The Sustained Release Excipients Market?

Companies operating within the sustained release excipients market are increasingly focused on creating advanced solutions, such as multifunctional polymer platforms, to improve drug formulation efficiency, decrease delivery time, and facilitate controlled-release profiles. These multifunctional polymer platforms refer to excipients capable of enabling immediate, delayed, and sustained drug release, while also being compatible with formulation technologies like hot melt extrusion and solubility-enhancing spray drying. For example, in September 2024, Evonik, a Germany-based company, commenced operations at a new spray drying facility located at its Darmstadt site, dedicated to EUDRAGIT polymers. This facility is designed to boost production capacity, shorten delivery times, and fully integrate with existing production networks. It incorporates green electricity and steam from local waste incineration, which is expected to reduce CO2 emissions by over 1,000 tons annually. Operating under IPEC-GMP pharmaceutical guidelines and directly linked to the production of aqueous dispersions, the facility minimizes transportation requirements and streamlines the supply chain. The polymers manufactured there support immediate, delayed, and sustained release formulations, thereby solidifying Evonik’s global leadership in oral drug delivery solutions and enhancing its capability to efficiently support innovative pharmaceutical development.

Which Leading Companies Dominate The Sustained Release Excipients Market Share?

Major companies operating in the sustained release excipients market are BASF SE, Ashland Global Holdings Inc, Colorcon Inc, Evonik Industries AG, Lubrizol Corporation, Merck KGaA, Roquette Freres, Shin Etsu Chemical Co Ltd, JRS Pharma GmbH Co KG, SPI Pharma Inc, Croda International Plc, Lonza Group AG, Chemische Fabrik Budenheim KG, Asahi Kasei Corporation, DuPont de Nemours Inc, Dow Chemical Company, Eastman Chemical Company, Gattefosse SAS, Balchem Corporation, Associated British Foods plc, Ransom Naturals Ltd, Cellulose Solutions Private Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report

How Does The Sustained Release Excipients Market Perform Across Major Global Regions?

North America was the largest region in the global sustained release excipients market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Sustained Release Excipients Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10822&type=smp

Browse Through More Reports Similar to the Global Sustained Release Excipients Market 2026, By The Business Research Company

Sustained Release Excipients Market Report 2026

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report

Pharmaceutical Excipient Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-excipient-global-market-report

Controlled Release Drug Delivery Market Report 2026

https://www.thebusinessresearchcompany.com/report/controlled-release-drug-delivery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the sustained release excipients market from 2025–2034 with trusted insights from The Business Research Company

What Is The Base Market Size For The Sustained Release Excipients Market Today And What Will It Reach By 2029?

The sustained release excipients market size has experienced robust growth over recent years. It is anticipated to expand from $1.4 billion in 2024 to $1.51 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.1%. This historical growth can be attributed to factors such as a rise in demand for controlled drug release, the prevalence of chronic diseases, improved patient compliance and convenience, innovations within the pharmaceutical industry, and regulatory backing for extended-release formulations.

The sustained release excipients market is projected to experience robust expansion over the coming years. It is set to reach $2.1 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.5%. This growth during the forecast period is primarily driven by an increasing elderly population, a heightened focus on personalized medicine, persistent challenges in patient adherence, the emergence of more complex drug formulations, continuous advancements in disease management, and the global expansion of healthcare. Prominent trends expected over this period include patient-centric approaches to drug delivery, strategic collaborations for formulation development, stringent regulatory compliance and safety measures, the worldwide proliferation of drug formulation technologies, and the increasing influence of biopharmaceuticals.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10822&type=smp

What Factors Are Boosting The Sustained Release Excipients Market?

The sustained-release excipients market is anticipated to experience growth due to the escalating prevalence of chronic and acute diseases. These illnesses are categorized distinctly based on their duration and progression. Chronic diseases are long-term medical conditions that typically last for three months or more, whereas acute diseases are characterized by a swift onset of symptoms that are usually severe but short-lived, often resolving within hours, days, or weeks. Sustained-release excipients are extensively employed in formulating pharmaceutical products for both chronic and acute conditions. Their benefits, including improved patient adherence, maintenance of consistent drug levels, reduction of side effects, and better disease management, contribute to increased sales of sustained-release excipients. For instance, in September 2022, the World Health Organization (WHO), a Switzerland-based specialized health agency, reported that cardiovascular diseases accounted for the largest share of non-communicable disease (NCD) deaths, totaling 17.9 million people annually. This was followed by cancer (9.3 million), chronic respiratory illnesses (4.1 million), and diabetes (2.0 million, which includes fatalities from renal disease caused by diabetes). Furthermore, an August 2022 report from the American College of Cardiology, a US-based non-profit medical association, projected an increase in all four major cardiovascular risk factors in the United States from 2025 to 2060. Diabetes is expected to show the most significant percentage rise, with a 39.3% increase to 55 million individuals. Hypertension is projected to increase by 25.1% to 162 million, dyslipidemia by 27.6% to 126 million, and obesity by 18.3% to 126 million. Additionally, substantial increases in cardiovascular disease rates are foreseen for stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), with ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million) also seeing significant rises. Consequently, the rising incidence of chronic and acute diseases acts as a primary driver for the growth of the sustained-release excipients market.

How Is The Sustained Release Excipients Market Categorized By Application, Type, And Region?

The sustained release excipients market covered in this report is segmented –

1) By Product: Gelatin, Polymers, Minerals, Sugars, Alcohol, Chitosan

2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration

3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation

Subsegments:

1) By Gelatin: Type A Gelatin, Type B Gelatin

2) By Polymers: Natural Polymers, Synthetic Polymers

3) By Minerals: Calcium Compounds, Magnesium Compounds, Other Mineral Excipients

4) By Sugars: Sucrose, Lactose, Glucose, Other Sugars

5) By Alcohol: Ethanol, Isopropyl Alcohol, Other Alcohols

6) By Chitosan: Low Molecular Weight Chitosan, High Molecular Weight Chitosan

How Are Technological Trends Affecting The Sustained Release Excipients Market Growth?

Product innovation stands out as a significant trend gaining momentum within the sustained release excipients market. Major companies operating in the sustained release excipients market are actively developing novel products to enhance their position. For example, in September 2022, Nutriventia Limited, an India-based pharmaceutical company, introduced Prolanza, a sustained-release ashwagandha ingredient (Withania somnifera). This advanced Ashwagandha root-only extract provides continuous support for stress reduction. Prolanza’s distinctive release mechanism allows its therapeutic effects to last over an extended period with just one daily dose. When compared to the control component, Prolanza ashwagandha exhibited superior relative absorption, improved bioavailability, and a prolonged elimination half-life, indicating a sustained-release profile. As ashwagandha is primarily used for its capacity to adapt and mitigate stress responses, Prolanza’s therapeutic effects will endure longer and have a greater overall positive influence on health. It is made from natural herbs and has been clinically verified for its effectiveness.

Who Are The Global Leaders Steering The Sustained Release Excipients Market Forward?

Major companies operating in the sustained release excipients market include BASF SE, Ashland Global Holdings Inc., Colorcon Inc., Croda International Plc, Dow Chemical Company, DuPont de Nemours Inc., Roquette Frères, Evonik Industries AG, Lubrizol Corporation, Merck KGaA, JRS Pharma GmbH & Co. KG, Shin-Etsu Chemical Co.Ltd., Gattefossé SAS, Eastman Chemical Company, Cellulose Solutions Private Limited, Avantor Inc., SPI Pharma Inc., Asahi Kasei Corporation, Chemische Fabrik Budenheim KG, Associated British Foods plc, Ransom Naturals Ltd, Balchem Corporation, IMCD Group, Lonza Group AG

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report

Which Region Is Projected To Achieve The Fastest Growth In The Sustained Release Excipients Market?

North America was the largest region in the global sustained release excipients market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=10822&type=smp

Browse Through More Reports Similar to the Global Sustained Release Excipients Market 2025, By The Business Research Company

Pharmaceutical Excipient Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmaceutical-excipient-global-market-report

Telemedicine Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/telemedicine-services-global-market-report

Animal Medicine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/animal-medicine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Future Market Size Estimation For The Sustained Release Excipients Market Covering 2025–2034?

The sustained release excipients market has demonstrated significant expansion in recent years. Its value is projected to rise from $1.4 billion in 2024 to $1.51 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.1%. This historical market expansion stems from factors such as a greater need for controlled drug release, the widespread occurrence of chronic illnesses, enhanced patient compliance and convenience, ongoing innovations in the pharmaceutical sector, and supportive regulations for extended-release formulations.

The sustained release excipients market is projected to experience substantial expansion over the upcoming years, with its size predicted to reach $2.1 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.5%. Key drivers behind this anticipated growth include the expanding elderly demographic, an emphasis on tailored medicine, difficulties with patient compliance, the proliferation of intricate drug formulations, improvements in disease treatment, and the worldwide growth of healthcare. Significant developments expected during this timeframe encompass drug delivery centered on patients, joint ventures for formulation creation, adherence to regulations and safety standards, the worldwide spread of drug formulation techniques, and the impact of biopharmaceutical products.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10822&type=smp

What Are The Drivers Pushing New Developments In The Sustained Release Excipients Market?

The future expansion of the sustained-release excipients market is anticipated to be driven by the increasing incidence of chronic and acute diseases. These illnesses represent two distinct classifications based on their duration and progression. Chronic conditions are long-term health issues persisting typically for three months or more, while acute conditions are characterized by a sudden onset of symptoms that are usually severe but short-lived, lasting from hours to days or weeks. Sustained-release excipients are extensively utilized in pharmaceutical formulations for both chronic and acute ailments, as they enhance patient adherence, maintain stable drug levels, mitigate side effects, and improve overall disease management, thereby boosting their sales. For instance, data from September 2022, provided by the World Health Organization (WHO), a specialized health agency based in Switzerland, indicated that cardiovascular diseases were responsible for the majority of NCD deaths, accounting for 17.9 million individuals annually. This was followed by chronic respiratory illnesses at 4.1 million, cancer at 9.3 million, and diabetes, including fatalities from renal disease associated with diabetes, at 2.0 million. Furthermore, a report released in August 2022 by the American College of Cardiology, a US-based non-profit medical association, projected a rise in all four major cardiovascular risk factors in the United States between 2025 and 2060. Diabetes is projected to experience the most significant percentage increase, with a 39.3% rise to 55 million people, followed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). Additionally, substantial increases in cardiovascular disease rates are expected for stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), with ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million) also seeing considerable growth. Consequently, the rising prevalence of chronic and acute diseases is a key factor propelling the sustained-release excipients market forward.

What Are The Major Segment Categories Driving The Sustained Release Excipients Market Growth?

The sustained release excipients market covered in this report is segmented –

1) By Product: Gelatin, Polymers, Minerals, Sugars, Alcohol, Chitosan

2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration

3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation

Subsegments:

1) By Gelatin: Type A Gelatin, Type B Gelatin

2) By Polymers: Natural Polymers, Synthetic Polymers

3) By Minerals: Calcium Compounds, Magnesium Compounds, Other Mineral Excipients

4) By Sugars: Sucrose, Lactose, Glucose, Other Sugars

5) By Alcohol: Ethanol, Isopropyl Alcohol, Other Alcohols

6) By Chitosan: Low Molecular Weight Chitosan, High Molecular Weight Chitosan

Which Market Trends Are Creating New Opportunities In The Sustained Release Excipients Industry?

Product innovation is a key trend gaining traction in the sustained release excipients market. Leading companies operating in the sustained release excipients market are developing new products to solidify their market position. For example, in September 2022, Nutriventia Limited, an India-based pharmaceutical company, launched Prolanza, a sustained-release ashwagandha ingredient (Withania somnifera). This advanced Ashwagandha root-only extract offers continuous support for stress reduction. Prolanza’s unique release mechanism enables it to demonstrate its therapeutic effects over an extended period with just one dose each day. When compared to the control component, Prolanza ashwagandha exhibited better relative absorption, improved bioavailability, and a longer elimination half-life, indicating a sustained-release profile. Because ashwagandha is primarily utilized for its ability to adapt and lessen stress responses, Prolanza’s therapeutic effects are expected to last longer and have a greater overall positive influence on health. It is made from natural herbs and has been clinically proven to work.

Who Are The Prominent Global Companies Shaping The Sustained Release Excipients Market?

Major companies operating in the sustained release excipients market include BASF SE, Ashland Global Holdings Inc., Colorcon Inc., Croda International Plc, Dow Chemical Company, DuPont de Nemours Inc., Roquette Frères, Evonik Industries AG, Lubrizol Corporation, Merck KGaA, JRS Pharma GmbH & Co. KG, Shin-Etsu Chemical Co.Ltd., Gattefossé SAS, Eastman Chemical Company, Cellulose Solutions Private Limited, Avantor Inc., SPI Pharma Inc., Asahi Kasei Corporation, Chemische Fabrik Budenheim KG, Associated British Foods plc, Ransom Naturals Ltd, Balchem Corporation, IMCD Group, Lonza Group AG

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report

How Is Sustained Release Excipients Market Demand Varying Across Different Regions?

North America was the largest region in the global sustained release excipients market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Sustained Release Excipients Market Report:

https://www.thebusinessresearchcompany.com/customise?id=10822&type=smp

Browse Through More Reports Similar to the Global Sustained Release Excipients Market 2025, By The Business Research Company

Pharmaceutical Excipient Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmaceutical-excipient-global-market-report

Telemedicine Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/telemedicine-services-global-market-report

Animal Medicine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/animal-medicine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Sustained Release Excipients Industry?

Over the past few years, the market size for sustained release excipients has been experiencing significant growth. An increase from $1.4 billion in 2024 to $1.51 billion in 2025 is projected, representing a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period is due to factors including a rise in demand for controlled drug release, the prevalence of chronic diseases, better patient compliance and convenience, innovations in the pharmaceutical industry, and regulatory support for extended-release formulations.

The market size of sustained release excipients is projected to witness significant expansion in the approaching years. Its value is anticipated to reach “$2.1 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.5%.” Factors influencing growth during the forecast period are an aging global population, emphasis on customized healthcare, hurdles in patient compliance, rise in sophisticated drug formulations, progression in disease control, and the expansion of healthcare worldwide. Key trends in the forecast period incorporate patient-focused drug delivery, partnerships for formulation development, adherence to regulatory mandates and safety, global growth of drug formulation technologies, and the impact of biopharmaceuticals.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10822&type=smp

What Forces Are Driving The Growth Of The Sustained Release Excipients Industry?

The sustained-release excipients market is poised to experience growth, thanks to the rising incidence of chronic and acute diseases. Chronic illnesses are medical conditions that last longer – usually three months or more, while acute diseases are typically intense but short-lived, lasting only a few hours to days or weeks. Sustained-release excipients, common in the formulation of pharmaceutical products for both disease types, has benefits like improving patient adherence, maintaining uniform drug levels, minimizing side effects, and bettering disease management, thereby enhancing sales. As per the World Health Organization (WHO) in September 2022, the maximum NCD deaths – 17.9 million annually, were due to cardiovascular diseases, followed by chronic respiratory diseases (4.1 million), diabetes-related complications including kidney disease (2.0 million), and cancer (9.3 million). In August 2022, a report from the American College of Cardiology predicted that all major cardiovascular risk factors in the United States would see an upward trend from 2025 to 2060, with diabetes showing the highest percentage increase of 39.3% to 55 million individuals, followed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). Also, cardiovascular disease rates for stroke and heart failure are expected to significantly increase (33.8% to 15 million and 33.4% to 13 million respectively), with ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million) also showing a marked increase. Thus, the escalating incidence of chronic and acute diseases is a significant factor driving the sustained-release excipients market’s growth.

The sustained release excipients market covered in this report is segmented –

1) By Product: Gelatin, Polymers, Minerals, Sugars, Alcohol, Chitosan

2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration

3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation

Subsegments:

1) By Gelatin: Type A Gelatin, Type B Gelatin

2) By Polymers: Natural Polymers, Synthetic Polymers

3) By Minerals: Calcium Compounds, Magnesium Compounds, Other Mineral Excipients

4) By Sugars: Sucrose, Lactose, Glucose, Other Sugars

5) By Alcohol: Ethanol, Isopropyl Alcohol, Other Alcohols

6) By Chitosan: Low Molecular Weight Chitosan, High Molecular Weight Chitosan

Which Emerging Trends And Strategic Shifts Are Shaping The Sustained Release Excipients Market?

One significant trend that is resurfacing in the sustained release excipients marketplace is product innovation. Key players in the market are designing and launching innovative products to cement their competitive place. For instance, Nutriventia Limited, a pharmaceutical firm based in India, introduced Prolanza, a sustained-release ashwagandha ingredient (Withania somnifera) in September 2022. Serving as an advance root-only extract of Ashwagandha, it provides an uninterrupted stress-reducing system. The exceptional release mechanism of Prolanza allows it to extend therapeutic effects over a prolonged duration with a single daily dosage. Compared to the control component, it showed superior relative absorption, enhanced bioavailability, and an extended elimination half-life, pointing to a prolonged-release pattern. Given that Ashwagandha is used primarily for its stress-relieving properties, Prolanza’s therapeutic benefits will last longer and provide boosted overall health benefits. It is derived from natural herbs and its effectiveness has been clinically validated.

Who Are The Primary Players Operating Across The Global Sustained Release Excipients Market?

Major companies operating in the sustained release excipients market include BASF SE, Ashland Global Holdings Inc., Colorcon Inc., Croda International Plc, Dow Chemical Company, DuPont de Nemours Inc., Roquette Frères, Evonik Industries AG, Lubrizol Corporation, Merck KGaA, JRS Pharma GmbH & Co. KG, Shin-Etsu Chemical Co.Ltd., Gattefossé SAS, Eastman Chemical Company, Cellulose Solutions Private Limited, Avantor Inc., SPI Pharma Inc., Asahi Kasei Corporation, Chemische Fabrik Budenheim KG, Associated British Foods plc, Ransom Naturals Ltd, Balchem Corporation, IMCD Group, Lonza Group AG

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report

Which Region Offers The Most Growth Potential For The Sustained Release Excipients Market Through 2029?

North America was the largest region in the global sustained release excipients market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10822&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Sustained Release Excipients Market Evolve in Terms of Growth and Size by 2029?

In the past few years, the market size for sustained release excipients has seen substantial growth. The market is projected to expand from $1.4 billion in 2024 to $1.51 billion in 2025, with an 8.1% compound annual growth rate (CAGR). This upward trend in the historical period can be credited to factors such as the rising demand for controlled drug release, the prevalent cases of chronic diseases, patient compliance and convenience, innovative strides in the pharmaceutical industry, and regulatory backing for extended-release formulations.

The market size of sustained release excipients is projected to significantly expand in the coming years, with an estimation of reaching $2.1 billion in 2029, growing at a compound annual growth rate (CAGR) of 8.5%. The driving forces behind this anticipated growth during the forecast period may be the growing elderly population, increased attention towards personalized medication, patient adherence challenges, the rise of complex drug formulations, advancements in disease management, and the expansion of global healthcare. Key trends predicted within this time frame include a focus on patient-focused drug delivery, partnerships for formulation development, regulatory compliance and safety, worldwide extension of drug formulation technologies, and the impact of biopharmaceuticals.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10822&type=smp

What factors are expected to fuel Sustained Release Excipients market growth in the coming years?

The sustained-release excipients market growth is anticipated to surge owing to the escalating prevalence of chronic and acute diseases. Chronic ailments, which last for an extended time, typically more than three months, and acute illnesses, characterized by rapid and usually severe but short-lived symptoms, are two categories that illnesses are classified into. The formulations of pharmaceutical products for both types of diseases extensively involve the use of sustained-release excipients. It enhances patient compliance, ensures uniform drug levels, minimizes side effects, and streamlines disease management, factors that augment the sales of sustained-release excipients. As reported by the World Health Organization (WHO), a health agency based in Switzerland, in September 2022, the most deaths from non-communicable diseases were due to cardiovascular diseases, amounting to 17.9 million people annually. This was followed by chronic respiratory diseases (4.1 million), diabetes (2.0 million, inclusive of deaths from kidney disease caused by diabetes), and cancer (9.3 million). An August 2022 report published by the American College of Cardiology, a non-profit medical association based in the US, projected significant rises from 2025 to 2060 in all four major cardiovascular risk factors in the US. It anticipates diabetes witnessing the highest proportional rise, soaring by 39.3% to 55 million individuals. This will be closely followed by dyslipidemia (increasing by 27.6% to 126 million), hypertension (rising by 25.1% to 162 million), and obesity (escalating by 18.3% to 126 million). Moreover, considerable rises are predicted in stroke rates (33.8% to 15 million) and heart failure (33.4% to 13 million), with ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million) right on their heels. Therefore, the burgeoning prevalence of chronic and acute diseases is projected to drive the growth of the sustained-release excipients market.

What Are The Key Findings From The Segmentation Analysis Of The Sustained Release Excipients Market?

The sustained release excipients market covered in this report is segmented –

1) By Product: Gelatin, Polymers, Minerals, Sugars, Alcohol, Chitosan

2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration

3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation

Subsegments:

1) By Gelatin: Type A Gelatin, Type B Gelatin

2) By Polymers: Natural Polymers, Synthetic Polymers

3) By Minerals: Calcium Compounds, Magnesium Compounds, Other Mineral Excipients

4) By Sugars: Sucrose, Lactose, Glucose, Other Sugars

5) By Alcohol: Ethanol, Isopropyl Alcohol, Other Alcohols

6) By Chitosan: Low Molecular Weight Chitosan, High Molecular Weight Chitosan

Which Trends Are Expected To Shape The Future Of The Sustained Release Excipients Market?

Innovations in product development are becoming a significant trend in the scar treatment market. Key market players are evolving skincare technology with the intention to boost treatment effectiveness, better patient outcomes, and offer non-invasive alternatives for those desiring scar diminution. The objective of this technology is to augment the efficiency of treatments, increase safety measures, and deliver ideal results for a range of skin worries. For example, Doctors Aesthetics Centre, a company based in India, introduced Picocare Majesty, an innovative laser skincare gadget, for the first time in South India in March 2023. This tool employs the latest picosecond technology to specifically address and manage diverse scar issues, encompassing acne scars, surgical scars, and pigmentation problems.

What Are The Most Active Companies In The Sustained Release Excipients Market Today?

Major companies operating in the sustained release excipients market include BASF SE, Ashland Global Holdings Inc., Colorcon Inc., Croda International Plc, Dow Chemical Company, DuPont de Nemours Inc., Roquette Frères, Evonik Industries AG, Lubrizol Corporation, Merck KGaA, JRS Pharma GmbH & Co. KG, Shin-Etsu Chemical Co.Ltd., Gattefossé SAS, Eastman Chemical Company, Cellulose Solutions Private Limited, Avantor Inc., SPI Pharma Inc., Asahi Kasei Corporation, Chemische Fabrik Budenheim KG, Associated British Foods plc, Ransom Naturals Ltd, Balchem Corporation, IMCD Group, Lonza Group AG

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report

Which Regional Markets Are Attracting The Most Investment In Sustained Release Excipients?

North America was the largest region in the global sustained release excipients market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10822&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model